Thymmune Therapeutics Announces Manish Jain as CTO

“Research has clearly shown that dysfunction of the thymus or its natural decline with aging  can lead to weaker immune system responses, but as of today there’s little people can do to improve their thymic health,” said Dr. Stan Wang, Founder & CEO of Thymmune. “We’ve developed a first-of-its-kind platform for restoring immune function through thymic cell engineering. With his proven ability to advance cell therapy products through the clinic and commercialize biopharmaceuticals, Manish will provide invaluable leadership at Thymmune during the company’s next phase of growth.”  

Mr. Jain brings to Thymmune over two decades of diverse experience in the biopharmaceutical industry, spanning from emerging biotechs to established global biopharma. Before joining Thymmune, Manish served as the CTO at Avenge Bio, focusing on the development of allogeneic encapsulated cell therapies for precise delivery of immune effector molecules targeting solid tumors. Prior to this role, he held the position of Vice President of Pharmaceutical Sciences & Manufacturing at Genocea, leading the CMC development and manufacturing efforts for neoantigen-based autologous T-cell therapy and cancer vaccines. Mr. Jain’s career also includes significant contributions at Momenta Pharmaceuticals, ImmunoGen, Amgen, and Human Genome Sciences, where he held various technical leadership roles involved in the development of multiple clinical and commercial drug products.

“In a short period of time, Thymmune has made extraordinary progress in the field of thymic cell engineering,” said Mr. Jain. “This work promises to not only help the numbers of patients each year that suffer from thymic disorder or dysfunction, but more broadly the global population of aging people who want to improve their immune system responses. I am honored to be part of a company that has the potential to affect the lives of so many.” 

Mr. Jain is joining Thymmune during a time of significant growth for the company. In 2023, Thymmune received $37 million in funding for the Thymus Rejuvenation project. The company is using this funding to advance best-in-class, human-induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) towards the clinic to restore immune function for patients in need.

About Thymmune

Thymmune is a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA. For more information, visit www.thymmune.com.